Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome

Bagley, Mark Christopher, Davis, Terence ORCID: https://orcid.org/0000-0003-2780-0262, Dix, Matthew, Fusillo, Vincenzo, Pigeaux, Morgane, Rokicki, Michal Jaroslaw and Kipling, David Glyn 2010. Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome. Future Medicinal Chemistry 2 (9) , pp. 1417-1427. 10.4155/fmc.10.217

Full text not available from this repository.

Abstract

Background: The ATP-competitive p38α MAPK inhibitor VX-745 exhibits an exquisite kinase selectivity profile, is effective in blocking p38 stress signaling in Werner syndrome dermal fibroblasts, has efficacy in clinical trials and may have therapeutic value against Werner syndrome. Previous synthetic routes, however, have only resulted in milligram quantities suitable for cell-based studies, whereas gram quantities would be required for in vivo use. Results & discussion: Microwave irradiation using a stop–flow monomodal microwave reactor has been found to facilitate scale-up of the synthesis of VX-745. Ullmann-type C–S bond formation using thiophenol, chloropyridazine, copper(I) catalyst and diol ligand proceeds rapidly and efficiently in this apparatus for elaboration to the pyrimido[1,6-b]pyridazinone core of VX-745 on gram scale and with good overall yield. Conclusion: This method delivers the p38 inhibitor VX-745 in sufficient quantities for preclinical studies to rescue the aging phenotype in Werner syndrome.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QD Chemistry R Medicine > R Medicine (General)
Publisher:	Future Science Ltd
ISSN:	1756-8919
Last Modified:	14 Dec 2022 02:16
URI:	https://orca.cardiff.ac.uk/id/eprint/47080

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item